Tumor invasive ability of papillary thyroid carcinomas is not conferred by acquired gene mutations. (October 2021)

• Record Type: Journal Article
• Authors: Tong, Mengying; Li, Shuang; Li, Yulong; Li, Ying; Feng, Yue; Che, Ying
• Is Part Of: Journal of investigative medicine. Volume 69:Number 7(2021)
• Page Start: 1382
• Page End: 1385
• Publication Date: 2021-10
• Subjects: thyroid neoplasms -- mutation; Clinical medicine -- Periodicals; Medicine -- Research -- Periodicals; Medicine; Research -- United States; Clinical medicine; Medicine -- Research; Periodicals; 616.075
• DOI: 10.1136/jim-2021-001971
• Languages: English
• ISSNs: 1081-5589

Abstract

Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer. The ability to predict whether a carcinoma would exhibit invasive ability in patients with PTC is important and has clinical implications for the selection of therapeutic strategies. Although several studies have focused on the genetic characterization of invasive cancer cells, the factors critical to the origination of invasive cancer cells are still unclear. This study aimed to determine whether genomic mutations contribute to the acquisition of the tumor invasion phenotype and to investigate the genetic features of invasive cancer cells in patients with PTC. We performed customized 48-gene deep exon sequencing in samples obtained from 88 patients with PTC via fine needle aspiration; the results revealed that no genetic changes were specifically associated with the tumor aggressiveness phenotype. Our results indicate that genetic mutations do not cause indolent PTCs to become invasive.